Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med 2020;382:1969-1973.32227757
Collins FS, Stoffels P. Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA 2020;323:2455-2457.32421150
Lurie N, Sharfstein JM, Goodman JL. The development of COVID-19 vaccines: safeguards needed. JAMA 2020 July 6 (Epub ahead of print).32628262
Pfizer. Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study. November 9 2020 (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against).
Moderna. Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study. November 16 2020 (https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy).
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615.33301246
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.33306989
Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397:671-681.33545094
Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 2020;324:951-960.32789505
World Health Organization. The COVID-19 candidate vaccine landscape and tracker (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines).
Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. January 28 2021 (https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3).
Johnson & Johnson. Johnson & Johnson COVID-19 vaccine authorized by U.S. FDA for emergency use — first single-shot vaccine in fight against global pandemic. February 27 2021 (https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial).
Cele S Gazy I Jackson L et al. Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. January 26 2021 (https://www.medrxiv.org/content/10.1101/2021.01.26.21250224v1). preprint.
Tegally H Wilkinson E Giovanetti M et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. December 22 2020 (https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1). preprint.
Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 2020;588:682-687.33045718
Greaney AJ, Loes AN, Crawford KHD, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 2021 February 8 (Epub ahead of print).33592168
Volz E Mishra S Chand M et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. January 4 2021 (https://www.medrxiv.org/content/10.1101/2020.12.30.20249034v2). preprint.
Wang P Liu L Iketani S et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. January 26 2021 (https://www.biorxiv.org/content/10.1101/2021.01.25.428137v1). preprint.
Public Health England. Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01. Technical briefing 5. 2021 (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/957504/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5_England.pdf).
Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med 2021 March 2 (Epub ahead of print).33654292
Voloch CM da Silva FR Jr de Almeida LGP et al. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro Brazil. December 26 2020 (https://www.medrxiv.org/content/10.1101/2020.12.23.20248598v1). preprint.
Gröhs Ferrareze PA Bonetti Franceschi V de Menezes Mayer A Dickin Caldana G Zimerman RA Thompson CE. E484K as an innovative phylogenetic event for viral evolution: genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. January 27 2021 (https://www.biorxiv.org/content/10.1101/2021.01.27.426895v1). preprint.
Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021 February 19 (Epub ahead of print).33617777
Emary KRW Golubchik T Aley PK et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7). February 4 2021. preprint.
Sattler A, Angermair S, Stockmann H, et al. SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition. J Clin Invest 2020;130:6477-6489.32833687
National Institute for Communicable Diseases. Dominance of the SARS-CoV-2 501Y.V2 lineage in Gauteng. January 28 2021 (https://www.nicd.ac.za/wp-content/uploads/2021/01/Dominance-of-the-SARS-CoV-2-501Y.V2-lineage-in-Gauteng-South-Africa-1.pdf.) preprint.
Muik A, Wallisch A-K, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 2021 January 29 (Epub ahead of print).33514629
Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med 2021;384:1466-1468.33596352
Janssen Vaccines & Prevention B.V. A randomized double-blind placebo-controlled phase 3 study to assess the efficacy and safety of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and Older. Clinical protocol. 2020 (https://www.jnj.com/coronavirus/covid-19-phase-3-study-clinical-protocol).
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467-478.32702298
McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 2021;590:630-634.33276369
Gavi the Vaccine Alliance. New collaboration makes further 100 million doses of COVID-19 vaccine available to low- and middle-income countries. 2020 (https://www.gavi.org/news/media-room/new-collaboration-makes-further-100-million-doses-covid-19-vaccine-available-low).
Amnesty International. COVID-19: Oxford/AstraZeneca vaccine a boost for global access but huge inequality remains. November 23 2020 (https://www.amnesty.org/en/latest/news/2020/11/oxford-astrazeneca-vaccine-a-boost-for-global-access-but-huge-inequality-remains).
McCarthy N. The cost per jab of Covid-19 vaccine candidates. Statista. December 1 2020. (https://www.statista.com/chart/23658/reported-cost-per-dose-of-covid-19-vaccines).
PANGO Lineages. Global report investigating novel coronavirus haplotypes. 2021 (https://cov-lineages.org/global_report.html).